New Faculty Recruitment to the Indiana University Gene Therapy Program

印第安纳大学基因治疗项目新教师招聘

基本信息

批准号：
7935348
负责人：
KENNETH CORNETTA
金额：
$ 28.92万
依托单位：
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
依托单位国家：
美国
项目类别：
财政年份：
2009
资助国家：
美国
起止时间：
2009-09-30 至 2012-08-31
项目状态：
已结题

项目摘要

DESCRIPTION (provided by applicant): The Gene and Cell Therapy Program (GCTP) at Indiana University is a highly interactive group of investigators with a 15-year history of multi-departmental interaction and collaborative research. The program has a focus on the genetic manipulation of stem cells and is home to a world-class facility for the manufacture of clinical gene therapy products (funded by a NCRR construction grant). Indiana University is the NHLBI designated site for clinical lentiviral vector production through its Gene Therapy Resources Program. Indiana University is also the site of the National Gene Vector Biorepository funded by the NCRR/NIH. A NHLBI funded Program Project Grant (PI Dinauer) has facilitated the collaborations in the GCTP. Moreover, a NHLBI funded training grant in gene therapy has trained 5 pre-doctoral students and 22 post-doctoral fellows. An NIDDK training grant in hematopoiesis has trained 22 pre-doctoral students and 26 post-doctoral fellows. This P30 application will enhance this interactive group of gene and cell therapy experts while providing a proven, productive environment for the development of junior faculty. Specific Aim: The aim of this proposal is to fund recruitment of a junior faculty with expertise in gene transfer that can facilitate clinical trial and develop novel production methodology. The individual we seek to move to a tenure track position is Scott Witting, Ph.D. This P30 grant will enhance the Gene and Cell Therapy Program at Indiana University. Dr. Scott Witting will be hired as an Assistant Professor tenure track and develop an independent research program aimed at identifying the optimal, clinically relevant, gene transfer methodology for transduction of hematopoieitic and other stem cell products. This will facilitate clinical trials proposed by the GCTP members.

描述（由申请人提供）：印第安纳大学的基因和细胞疗法计划（GCTP）是一个高度互动的研究人员，具有15年的多部门互动和协作研究历史。该计划的重点是对干细胞的基因操纵，并且是世界一流的临床基因治疗产品（由NCRR建筑拨款资助）生产的世界一流设施。印第安纳大学是NHLBI通过其基因治疗资源计划的NHLBI指定的临床病毒载体生产地点。印第安纳大学也是由NCRR/NIH资助的国家基因载体生物座的所在地。 NHLBI资助的计划项目赠款（PI Dinauer）促进了GCTP的合作。此外，NHLBI资助的基因疗法培训补助金已经培训了5名博士后学生和22名博士后研究员。 NIDDK的造血培训补助金已培训了22名博士后学生和22名博士后研究员。该P30应用将增强这一互动基因和细胞疗法专家的互动群体，同时为开发初级教师提供了一个经过验证的生产环境。具体目的：该提案的目的是资助具有基因转移专业知识的初级教师的招聘，该教师可以促进临床试验并开发新的生产方法。斯科特·威特（Scott Witting），我们寻求搬到任期轨道职位的个人是博士学位。该P30赠款将增强印第安纳大学的基因和细胞疗法计划。斯科特·威特（Scott Witting）博士将被聘为助理教授任期轨道，并制定一个独立的研究计划，旨在确定用于转导造血和其他干细胞产品的最佳，临床相关的基因转移方法。这将促进GCTP成员提出的临床试验。